Cardiff Oncology: Expecting Massive Updates In Colon Cancer Soon

Group 1 - Cardiff Oncology (NASDAQ: CRDF) is emerging as a notable player in the colorectal cancer (CRC) biotech sector, with promising results from their randomized phase 2 trial [1] - The company has demonstrated significant potential in addressing CRC, which is a critical area in oncology [1] Group 2 - The article emphasizes the importance of understanding the science behind biotech investments to make informed decisions [1]